A pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists.


Updates from The Motley Fool

Latest updates on Aradigm from Fool.com.

There is no available coverage of Aradigm at this time.



Stock Performance

ARDM vs. S&P 500 | 2 Year Performance
View Interactive ARDM Charts
Sponsored by

Key Data Points

Primary metrics and data points about Aradigm.
Current Price: $4.41
Prev Close: $4.69
Open: $4.43
Bid: $4.40
Ask: $7.49
Day's Range: $4.41 - $4.43
52wk Range: $2.60 - $7.90
Volume: 200
Avg Vol 4,521
Market Cap: $65.10M
P/E (ttm): -2.86
EPS (ttm): -$1.64
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Aradigm.
CAPS Rating 0 out of 5
 
5 Outperform
0 Underperform
CAPS All Stars
 
1 Outperform
0 Underperform

How do you think Aradigm will perform against the market?



You pick for Aradigm is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Igor Gonda, CEO

0% Approve

Based on 0 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Aradigm.

A pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers